熱門資訊> 正文
华尔街欢呼Ziihera方案获得批准，Zymeworks走高
2026-08-26 23:19
- Zymeworks (ZYME) is trading ~8% higher Wednesday as some Street analysts voiced bullish sentiments for the stock after the FDA on Tuesday approved two regimens containing Jazz Pharmaceuticals' (JAZZ) cancer therapy Ziihera, which they licensed.
- H.C. Wainwright's Robert Burns noted that the approval triggers a $250M milestone payment to Zymeworks from Jazz. He maintained his buy rating and raised his price target to $55 from $51 (~100% upside based on Aug. 25 close).
- Citizens' Reni Benjamin has a market outperform rating on the stock with a bull case price target of $40 (~46% upside). He projects Ziihera royalties will significantly contribute to the bottom line in the coming years.
- He also highlighted pipeline assets ZW191 and ZW251. The former is in phase 1 for advanced solid tumors, while the latter, an antibody-drug conjugate, is also in phase 1 for liver cancer.
More on Zymeworks
- A Post Acquisition Look At Zymeworks
- Here's Why Zymeworks Inc. Paid $929 Million For Theravance Biopharma
- Zymeworks Inc. (ZYME) M&A Call - Slideshow
- Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks
- Zymeworks gains following addition to Citi catalyst watch
推薦文章
華盛早報 | 美聯儲鷹派加息「嚇壞」美股！沃什再度拒絕給出點陣圖；OpenAI提議設立AI安全報告機制；NEBIUS上調英偉達GPU租賃價
今夜加息概率升破92%！全球風暴即將來襲？覆盤近三輪加息周期，這次會走2015還是2022年劇本？
5%美債收益率風暴來襲！再融資炸彈倒計時開啟，誰會是第一個犧牲品？
美參議院加密市場結構法案程序性投票未獲通過 兩黨談判破裂致立法進程受阻
利率決議前夕黃金「搶跑」！美聯儲兩難困境正被看穿：加息是利空出盡，不加息金價衝5000？
扎克伯格稱更青睞依靠評估人員確保AI安全 而非放緩發展
攜程2026Q2淨利潤同比下降，受處罰費用影響，錄得淨虧損24億元！
加密貨幣法案折戟美國參議院！比特幣、以太幣跌至6月來最低
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
